Concepedia

James A. Monn

JA

8

Publications

908

Citations

8

H-Index

1997

Active since

Affiliations

Eli Lilly (United States)(Current)

James A. Monn is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and neuropharmacology.

Top concepts

Publications per year

1997–2001

8

Publications

8

Physiological Antagonism between 5-Hydroxytryptamine2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex

Gerard J. Marek, Rebecca A. Wright, Darryle D. Schoepp et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 279 citations

The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behaviors in Rats

Jayne Cartmell, James A. Monn, Darryle D. Schoepp · Journal of Pharmacology and Experimental Therapeutics · 1999 · 268 citations

In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats

Giuseppe Battaglia, James A. Monn, Darryle D. Schoepp · Neuroscience Letters · 1997 · 163 citations

, , +12

The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing

Jayne Cartmell, James A. Monn, Darryle D. Schoepp · European Journal of Pharmacology · 2000 · 90 citations

, , +8

Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia

Amy G.M Lam, Marc A. Soriano, James A. Monn et al. · Neuroscience Letters · 1998 · 43 citations

, , +10

Rows per page

1–5 of 8